The Hearing Review
  • Hearing Loss
    • Health & Wellness
    • Hearing Disorders
    • Patient Care
    • Prevention
    • Tinnitus
    • Vestibular
  • Products
    • Amplification
    • Hearing Aids
    • Implants & Bone Conduction
    • Tinnitus Devices
    • Vestibular Solutions
    • Accessories
  • Practice Building
    • Marketing
    • Office Services
    • Practice Management
  • Inside Hearing
    • Events
    • Industry News
    • People
    • Organizations
    • Regulation
    • Research
  • Resources
    • Videos
    • Webinars
    • White Papers
  • Edition Archive

Select Page

Tag: Thomas Meyer

All

Latest
Experts Confirm Betahistine’s Clinical Utility in the Treatment of BPPV

Experts Confirm Betahistine’s Clinical Utility in the Treatment of BPPV

Altamira Therapeutics reports that a meta-analysis of nine randomized controlled trials has shown that the oral administration of betahistine, along with the Epley maneuver, is more effective than Epley's maneuver alone.

  • Auris Medical Completes Enrollment in Phase 2 Study for Vertigo Drug

  • Auris Medical Announces Notice of Allowance for European Patent Application

  • Auris Medical Receives Notice of Allowance from Patent Offices for Vertigo Drug

  • Auris Medical Forms Scientific Advisory Board for Tinnitus Research and Development

  • Auris Medical Announces Publication on Study Showing Effect of Betahistine on Vertigo Symptoms

  • Auris Medical Announces Clinical Results from AM-111 Phase 3 Clinical Trial

All

Latest
Auris Medical Holding AG Announces Patient Recruitment for Phase 3 Clinical Trial of Tinnitus Drug is Complete

Auris Medical Holding AG Announces Patient Recruitment for Phase 3 Clinical Trial of Tinnitus Drug is Complete

Keyzilen® is a small molecule N-methyl-D-aspartate (NMDA) receptor antagonistin that is in development for treatment of acute tinnitus of the inner ear.

  • Auris Medical Holding AG Completes Patient Enrollment in Phase 3 Clinical Trial of Hearing Loss Drug

    Auris Medical Holding AG Completes Patient Enrollment in Phase 3 Clinical Trial of Hearing Loss Drug

  • Auris Announces FDA Fast Track Designation For AM-111

    Auris Announces FDA Fast Track Designation For AM-111

  • Auris Medical Collaborates with Cochlear on Clinical Trial

    Auris Medical Collaborates with Cochlear on Clinical Trial

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

The Hearing Review

7300 W 110th St – Floor 7
Overland Park, KS 66210
(913) 955-2600

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Press Releases

Key Resources

Digital Edition

Podcasts

Webinars

White Papers

Videos

Helpful Links

Media Solutions Kit

Subscribe Now

Contact Us

Submit an Article

  • Follow
  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2024 MEDQOR LLC. All Rights Reserved

✖